Product Description
Bevacizumab biosimilar
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Colorectal Cancer|Liver Cancer
Phase 2: Mesothelioma
Phase 1: Blast Crisis|Lymphoma, Non-Hodgkin|Juvenile Myelomonocytic Leukemia,|Myelodysplastic-Myeloproliferative Diseases|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Adenocarcinoma|Myeloid, Accelerated Leukemia|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Soft Tissue Cancer|Pancreatic Cancer|Myeloproliferative Disorders|Lymphoma, B-Cell|Anemia, Refractory|Breast Cancer|Ovarian Cancer|Prostate Cancer|Leukemia, Plasma Cell|Myelofibrosis|Breast Diseases|Acute Myelomonocytic Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Chronic Myeloid Leukemia|Thrombocytosis|Sarcoma|Multiple Myeloma|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| The PUMP Trial | P3 |
Recruiting |
Colorectal Cancer|Liver Cancer |
2029-06-30 |
|
| STUDY00020679 | P1 |
Withdrawn |
Ovarian Cancer|Soft Tissue Cancer|Breast Cancer|Sarcoma|Prostate Cancer|Pancreatic Cancer |
2026-05-31 |
|
| NCI-2021-08573 | P2 |
Recruiting |
Mesothelioma |
2025-08-20 |
|
| SIBP04-02 | P3 |
Completed |
Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma |
2022-12-26 |
31% |